Israel Active

Dror Ortho-Design has successfully completed user experience trials for its ZSmile platform (see previously) ahead of commercial release. Feedback has been integrated for ZSmile to begin manufacture and distribution in Israel in the first half of 2025. 250 patients have already been treated.

Tel Aviv University researchers used AI tools to discover what motivates people to exercise. They found that 23.9% of those who engage in sports do so to improve their appearance, 18.9% exercise to maintain their physical health, and 16.9% exercise to maintain their mental health.

Researchers from Tel Aviv University (Dan Peer’s lab) utilized CRISPR to cut the SOX2 gene from cancer cells of head and neck tumors – and in lab tests successfully eliminated 50% of the tumors. The breakthrough defied general belief that knocking out a single gene wouldn’t have any effect.

Researchers at Israel’s Technion Institute have discovered that a protein in breast milk facilitates the passage of nanoparticles through the intestinal wall, delivering essential nutrients to the baby. Mimicking this mechanism, can protect medications from the digestive system and allow non-needle delivery.

Over 500 Jewish doctors and healthcare professionals, including 260 doctors, gathered at the 10th annual MedEx event in Teaneck, New Jersey. The International Medical Aliyah Program (IMAP) started MedEx to bring 2,000 Jewish doctors to Israel. In 2024 alone it brought 519.

Israel’s Enovid (see previously) has now launched its SaNOtize Nitric Oxide Nasal Spray as NOWONDER in the US. NOWONDER delivers advanced nasal cleansing, viral protection (e.g. against COVID-19), and sinus health support.

An Israeli-led research team has analyzed how the brain processes speech and transforms sounds into conversation. It could lead to new advancements in speech recognition technology, tools for people with speech disorders, and personalized assistive devices.

Israel’s Purple Biotech (see previously) has partnered with the Icahn School of Medicine at Mount Sinai New York, to develop CAPTN-3, a platform of activated antibodies. The aim is to enhance tumor-specific immunity against various cancer types.

Israel’s OncoRedox is developing a new platform for the early diagnosis and monitoring of cancer and chronic diseases. Its disposable sensor plus AI-powered technology is designed to detect and profile cell-free metabolites within minutes, providing a unique metabolic fingerprinting.

A discovery by Weizmann scientists has astounded the world of microbiology (and the BBC). Every cell in the human body makes bacteria-killing chemicals to recycle proteins. These natural antibiotics could transform future research into combating resistant bacteria.